In vitro quality of single‐donor platelets treated with riboflavin and ultraviolet light and stored in platelet storage medium for up to 8 days

Cookson, P.; Thomas, Stephen; Marschner, Susanne; Goodrich, Raymond P.; Cardigan, Rebecca

doi:10.1111/j.1537-2995.2011.03388.x

Cited by 26 publications

(48 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, a comparison of two PASs showed that phosphate helps maintain the pH in Mirasol-treated PLT concentrates. 26 In contrast, the elevated CD62P expression seems to be initiated by a different pathway that is more directly targeted by the Mirasol procedure. Despite the fact that a rise in CD62P expression and annexin A5 binding are almost always seen together, in our study we find a decoupling of the two processes, which has been described recently in vitro using different stimuli.…”

Section: Discussionmentioning

confidence: 91%

Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 91%

Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Cookson et al observed mean losses of 11% FV and 33% FVIII activities relative to baseline values and lesser declines of FII, FVII, FIX, and FXII after 144 hours of refrigerated storage of thawed FP made from whole blood held at room temperature for 24 hours. These factor losses failed to affect thrombin generation and produced only marginal lengthening of clot time, but no change in clot strength, in viscoelastic testing [77]. …”

Section: Overview: Assessing the Quality Of Transfusable Plasmamentioning

confidence: 99%

Quality Assessment of Established and Emerging Blood Components for Transfusion

Acker

Marks

Sheffield

2016

Journal of Blood Transfusion

View full text Add to dashboard Cite

Blood is donated either as whole blood, with subsequent component processing, or through the use of apheresis devices that extract one or more components and return the rest of the donation to the donor. Blood component therapy supplanted whole blood transfusion in industrialized countries in the middle of the twentieth century and remains the standard of care for the majority of patients receiving a transfusion. Traditionally, blood has been processed into three main blood products: red blood cell concentrates; platelet concentrates; and transfusable plasma. Ensuring that these products are of high quality and that they deliver their intended benefits to patients throughout their shelf-life is a complex task. Further complexity has been added with the development of products stored under nonstandard conditions or subjected to additional manufacturing steps (e.g., cryopreserved platelets, irradiated red cells, and lyophilized plasma). Here we review established and emerging methodologies for assessing blood product quality and address controversies and uncertainties in this thriving and active field of investigation.

show abstract

“…Although platelet activation by Mirasol treatment has been observed, the biological effect of this activation did not lead to acute lung injury [18, 27]. However, a recent work suggests that platelet transfusion clinical effectiveness might be reduced due to decreased normal platelet function after PRT procedures [28].…”

Section: Discussionmentioning

confidence: 99%

Mirasol pathogen reduction technology treatment of human whole blood does not induce acute lung injury in mice

et al. 2017

Self Cite

View full text Add to dashboard Cite

In resource-limited settings and in the military theater, fresh human whole blood is commonly transfused, but infectious risks are a concern. Sophisticated molecular testing for potential infectious agents in the whole blood is often unavailable. To address this unmet need, pathogen reduction technology (PRT) has been developed, and it is an effective approach to inactivate a broad range of pathogens found in human blood. However, studies are needed to determine if it is harmful to blood cells and whether these cells could damage the transfused recipient, including the development of acute lung injury/acute respiratory distress syndrome. In this study, we used a commercial PRT system to treat human whole blood that was then transfused into immunodeficient mice, and the development of acute lung injury was determined. In a model of transfusion-related acute lung injury (TRALI), BALB/c SCID mice developed more robust lung injury when challenged with a MHC Class I monoclonal antibody compared to BALB/c wild-type and NOD/SCID mice. Transfusion of control versus Mirasol PRT-treated whole blood (25% blood volume exchange) into BALB/c SCID mice did not produce lung injury at storage day 1. However, mild lung injury at storage days 14 and 21 was observed without significant differences in lung injury measurements between Mirasol PRT-treated and control groups. The mild storage-dependent acute lung injury correlated with trends for increased levels of cell-free hemoglobin that accumulated in both the control and Mirasol PRT-treated groups. Neutrophil extracellular traps were elevated in the plasma of BALB/c SCID mice in the monoclonal antibody TRALI model, but were not different in mice that received exchange transfusions. In conclusion, exchange transfusion of human whole blood into immunodeficient mice produces mild lung injury that is storage-dependent and not related to pathogen reduction treatment.

show abstract

In vitro quality of single‐donor platelets treated with riboflavin and ultraviolet light and stored in platelet storage medium for up to 8 days

Abstract: Mirasol treatment of PLTs followed by storage in PSM results in increased PLT activation and metabolism to a level similar to that reported for PLTs treated and stored in plasma. Units treated at a low volume (<150 mL) showed poor in vitro quality.

Cited by 26 publications

References 40 publications

Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?

Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?

Quality Assessment of Established and Emerging Blood Components for Transfusion

Mirasol pathogen reduction technology treatment of human whole blood does not induce acute lung injury in mice

Contact Info

Product

Resources

About